Hope Rugo, Professor of Medicine and Director of the Breast Oncology Clinical Trials Program at the University of California at San Francisco, shared a post on X:
“Today NEJM published my DESTINY Breast-05 editorial discussing the implications of these practice changing data for pts with high risk HER2+ ESBC along with choice of neoadjuvant Rx, toxicity, and ongoing trials.
Exciting times! ”
Title: Hitting the Mark – Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer
Author: Hope Rugo
Read the Full Article.
Other articles featuring Hope Rugo on OncoDaily.